Your session is about to expire
← Back to Search
ADI PEG20 for Uveal Melanoma
Study Summary
This trial is testing a new combination treatment for advanced uveal melanoma. The goal is to see if it is safe and effective.
- Uveal Melanoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA given its stamp of approval to ADI PEG20?
"There is only minimal evidence that ADI PEG20 offers a safe and effective treatment, so it received the lowest rating of 1 on our scale."
How many individuals are involved in this experiment?
"As of now, this clinical trial is not seeking out new participants. This medical study was first published on April 16th 2019 and last updated January 10th 2022. For those looking for alternative trials connected to uveal neoplasms, 755 are currently recruiting patients while there are 764 studies actively enrolling individuals that would benefit from ADI PEG20 therapy."
Could patients join this investigation at the present time?
"Unfortunately, this clinical study is not actively recruiting for participants as per the latest update on clinicaltrials.gov dated January 10th 2022. Despite that, there are numerous other trials currently in progress and seeking candidates - 1,519 to be exact."
Are there any further investigations into the effects of ADI PEG20?
"Presently, there are 764 clinical trials being conducted for ADI PEG20; 86 of those studies have reached Phase 3. The majority of tests are being carried out in Pittsburgh, Pennsylvania while a total of 42760 sites across the world host these tests."
What maladies does ADI PEG20 typically alleviate?
"ADI PEG20 is commonly used for anti-angiogenic therapy, but it can also be employed to manage a variety of malignancies like squamous cell carcinoma and melanomas that have become resistant to traditional treatments."
Share this study with friends
Copy Link
Messenger